Harvard Management Company’s Xilio Therapeutics XLO Stock Holding History

Harvard Management Company’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-29,719	Closed	-$878K	–	22
2023 Q3	$878K	Hold	29,719	–	–	0.1%	19
2023 Q2	$1.09M	Hold	29,719	–	–	0.11%	26
2023 Q1	$1.32M	Hold	29,719	–	–	0.14%	37
2022 Q4	$1.12M	Hold	29,719	–	–	0.14%	40
2022 Q3	$1.21M	Hold	29,719	–	–	0.15%	41
2022 Q2	$1.22M	Hold	29,719	–	–	0.14%	39
2022 Q1	$2.94M	Hold	29,719	–	–	0.3%	34
2021 Q4	$6.66M	Buy	+29,719	New	+$7.09M	0.62%	35

Other funds holding XLO

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Harvard Management Company's XLO Position: Q4 2023 in Review

Harvard Management Company sold out of Xilio Therapeutics (XLO) in Q4 2023, closing a stake of 29,719 shares — an estimated $878K sold.

Harvard Management Company first reported a position in XLO in Q4 2021 and held it in 8 quarters. The position peaked at $6.66M in Q4 2021. 33 funds tracked by Wall St. Rank hold XLO as of Q4 2023.

Harvard Management Company reported no remaining Xilio Therapeutics position as of Q4 2023 after selling out during the quarter.
Harvard Management Company sold 29,719 Xilio Therapeutics shares in Q4 2023, an estimated $878K.
Harvard Management Company first reported a position in Xilio Therapeutics in Q4 2021 and held it in 8 quarters.
Harvard Management Company's Xilio Therapeutics position peaked at $6.66M in Q4 2021.
33 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2023.

Based on Harvard Management Company's 13F filing for Q4 2023, filed 9 Feb 2024.